Exelixis
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.About EXEL
Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
Stock Snapshot
As of today, Exelixis(EXEL) shares are valued at $58.49. The company's market cap stands at 14.49B, with a P/E ratio of 17.83.
On 2026-09-18, Exelixis(EXEL) stock traded between a low of $56.75 and a high of $58.52. Shares are currently priced at $58.49, which is +3.1% above the low and -0.1% below the high.
The Exelixis(EXEL)'s current trading volume is 1.69M, compared to an average daily volume of 2.01M.
During the past year, Exelixis(EXEL) stock moved between $33.76 at its lowest and $59.72 at its peak.
During the past year, Exelixis(EXEL) stock moved between $33.76 at its lowest and $59.72 at its peak.
EXEL News
has delivered a strong multi year share price run, and the question now is whether that move lines up with what the company earns today. With the stock recently...
...
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza...
Analyst ratings
57%
of 21 ratingsMore EXEL News
Exelixis (EXEL) is back in focus after the FDA extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer by three months, followin...
Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tu...
Stifel Nicolaus analyst Stephen Willey has maintained their neutral stance on EXEL stock, giving a Hold rating on September 1. Stephen Willey has given his Hol...
On Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘s (NASDAQ:EXEL) new drug application (NDA) for zanzalintinib...
William Blair is “surprised” by the three-month delay of the PDUFA date for Exelixis (EXEL)’ new drug application for zanzalintinib in combination with atezoliz...
Technology Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay Licensing Exelixis (EXEL) stock dropped out of a buy zone Friday after the...
An update from Exelixis ( (EXEL) ) is now available. On September 10, 2026, Exelixis, Inc. received notice from the U.S. Food and Drug Administration that the...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.